Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma : Combination therapy improves time to progressionORLOWSKI, Robert Z; NAGLER, Arnon; SPICKA, Ivan et al.Journal of clinical oncology. 2007, Vol 25, Num 25, pp 3892-3901, issn 0732-183X, 10 p.Article

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myelomaVIJ, Ravi; HORVATH, Noemi; SPENCER, Andrew et al.American journal of hematology. 2009, Vol 84, Num 10, pp 650-656, issn 0361-8609, 7 p.Article

Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivoFARRUGIA, Amanda N; ATKINS, Gerald J; TO, L. Bik et al.Cancer research (Baltimore). 2003, Vol 63, Num 17, pp 5438-5445, issn 0008-5472, 8 p.Article

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1LING, Silvia C. W; LAU, Edwin K. K; JOSHUA, Douglas E et al.Haematologica (Roma). 2012, Vol 97, Num 1, pp 64-72, issn 0390-6078, 9 p.Article

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaILAND, Harry; BRADSTOCK, Ken; BROWETT, Peter et al.Haematologica (Roma). 2012, Vol 97, Num 2, pp 227-234, issn 0390-6078, 8 p.Article